Person: ALİ, RIDVAN
Loading...
Email Address
Birth Date
25 results
Search Results
Now showing 1 - 10 of 25
Publication Evaluation of patients with pnh treated by eculizumab: Real world data from turkey(Amer Soc Hematology, 2019-11-13) Karadag, Fatma Keklik; Yenerel, Mustafa Nuri; Mehmet, Yilmaz; Teke, Hava Uskudar; Özkocaman, Vildan; Tuglular, Tulin; Erdem, Fuat; Unal, Ali; Ayyildiz, Orhan; Ozet, Gulsum; Ozkan, Melda; Kaya, Emin; Ayer, Mesut; Salim, Ozan; Guvenc, Birol; Ozdogu, Hakan; Mehtap, Ozgur; Sonmez, Mehmet; Guler, Nil; Hacioglu, Sibel Kabukcu; Aydogdu, Ismet; Bektas, Ozlen; Toprak, Selami Kocak; Kaynar, Lale; Yagci, Munci; Aksu, Salih; Tombak, Anil; Karakus, Volkan; Yavasoglu, Irfan; Onec, Birgul; Ozcan, Mehmet Ali; Undar, Levent; Ali, Ridvan; Ustun, Celalettin; Ilhan, Osman; Saydam, Guray; Sahin, Fahri; ÖZKOCAMAN, VİLDAN; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; AAH-1854-2021; GXD-8209-2022Publication Fatal cryptococcal meningitis in a patient with chronic lymphocytic leukemia(Pagepress Publ, 2012-01-01) Dizdar, Oğuzhan Sıtkı; Karakeçili, Faruk; Coşkun, Belkıs Nihan; COŞKUN, BELKIS NİHAN; Ener, Beyza; ENER, BEYZA; Ali, Rıdvan; ALİ, RIDVAN; Mistik, Reşit; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı.; D-6213-2013; AAG-8523-2021; AAG-7155-2021Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections, especially opportunistic infections. We have described a patient with CLL who had cryptococcal meningitis. Despite lack of previous immunosuppressive treatment history, the patient experienced serious and fatal fungal infection. Physicians should be alert for a diagnosis of cryptococcal meningitis in patient with CLL who developed fever and headache.Publication The role of white blood cell count in perianal pathologies: A retrospective analysis of hematologic malignancies(Mattioli 1885, 2022-07-01) Orhan, Bedrettin; Özkalemkaş, Fahir; Özkocaman, Vildan; Gürbüz, Büsra; Ersal, Tuba; Pınar, İbrahim Ethem; Yalçın, Cumali; Candar, Ömer; Çubukcu, Sinem; Koca, Tuba Güllü; Ali, Rıdvan; ORHAN, BEDRETTİN; ÖZKALEMKAŞ, FAHİR; ÖZKOCAMAN, VİLDAN; GÜRBÜZ, BÜŞRA; ERSAL, TUBA; PINAR, İBRAHİM ETHEM; YALÇIN, CUMALİ; CANDAR, ÖMER; ÇUBUKÇU, SİNEM; GÜLLÜ KOCA, TÛBA; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0001-9907-1498; 0000-0003-4168-2821; 0000-0002-5129-2977; 0000-0002-5564-8862; 0000-0001-7602-6926; JWP-2738-2024; ACW-2157-2022; GWQ-5007-2022; KIE-5102-2024; JGM-6601-2023; GMY-8535-2022; FQG-8981-2022; JJB-0254-2023; GWQ-5007-2022; GXD-8209-2022; AAJ-4354-2021Background and Objective: Infections are the most common cause of anal and perianal pathologies in patients with hematological malignancies. Perianal infection diagnosis in this group of patients is difficult; thus, a careful anorectal examination is necessary with imaging modalities. In addition, the literature reveals a knowledge gap in the approach to anal pathologies in patients with neutropenia during diagnosis or chemotherapy. This study aimed to examine our institutional data on perianal complications and investigate the relationship between the white blood cell-neutrophil count, perianal lesion, and the type of treatment in patients with hematologic malignancies during the neutropenic period.Methods: Patients with a hematologic malignancy, hospitalized for cytotoxic chemotherapy, complicated by perianal pathology, documented by at least one imaging method, were included in the study.Results: A total of 42 patients were included in the study. Most of them had acute leukemia, 31 were affected by acute myeloid leukemia (AML), and 7 by Acute lymphoid leukemia (ALL). There was no statistically significant relationship between the anal abscess formation, the neutrophil count, and a previous perianal pathology. Anal abscess development was significantly more frequent in acute myeloid leukemia. An inverse relationship was found between the total white blood cell number at onset and having a surgical intervention for anal pathology.In conclusion, this article has shown that white blood cell count at the time of hospitalization can affect the surgical intervention in patients with hematological malignancy (in the majority with acute leukemia) affected by anal pathologies occurring in the neutropenic period.Publication Invasive pulmonary aspergillosis in acute leukemia: Current issues for pathogenesis, diagnosis and treatment(Bentham Science, 2006-01-01) Ali, Rıdvan; Özçelik, Tülay; ALİ, RIDVAN; Özçelik, Tülay; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Bölümü; GXD-8209-2022; JGT-3036-2023Invasive pulmonary aspergillosis (IPA) is a frequently life-threatening fungal infection that complicates acute leukemia patients following conventional chemotherapy and bone marrow transplantation. The mortality rate reaches 50% in leukemic patients during chemotherapy-induced neutropenia and can exceed 90% in bone marrow transplantation patients. Despite advances in antimicrobial therapy and supportive care, IPA remains a major clinical problem in patients with acute leukemia. Current issues for IPA in adults are reviewed.Publication Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: A multicenter retrospective analysis.(E-century Publishing Corp, 2021-01-01) Karadag, Fatma Keklik; Yenerel, Mustafa Nuri; Yilmaz, Mehmet; Uskudar, Hava; Tuglular, Tulin Firatli; Erdem, Fuat; Unal, Ali; Ayyildiz, Orhan; Ozet, Gulsum; Comert, Melda; Kaya, Emin; Ayer, Mesut; Salim, Ozan; Guvenc, Birol; Ozdogu, Hakan; Mehtap, Ozgur; Sonmez, Mehmet; Guler, Nil; Hacioglu, Sibel; Aydogdu, Ismet; Bektas, Ozlen; Toprak, Selami Kocak; Kaynar, Lale; Yagci, Munci; Aksu, Salih; Tombak, Anil; Karakus, Volkan; Yavasoglu, Irfan; Onec, Birgul; Ozcan, Mehmet Ali; Undar, Levent; Ilhan, Osman; Saydam, Guray; Sahin, Fahri; Ozkocaman, Vildan; ÖZKOCAMAN, VİLDAN; Ali, Ridvan; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0003-2687-9167; 0000-0002-7798-4349; 0000-0001-8605-8497; 0000-0003-1977-0104; 0000-0002-8902-1283; 0000-0002-2176-4371; 0000-0003-0604-6475; 0000-0003-0757-9206; 0000-0001-7717-5827; 0000-0002-7195-1845; 0000-0001-9178-2850; 0000-0003-2824-1044; 0000-0001-7842-9702; AAA-2012-2021; S-4300-2019; GLU-6163-2022; HRC-6282-2023; ABH-5764-2020; W-2951-2017; ABE-4485-2021; ITT-2117-2023; IZQ-0529-2023; W-3827-2017; GLQ-6094-2022; HKM-4739-2023; ABC-8182-2021Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.Publication Evaluation of sexual dysfunction in patients with hematological malignancies(Elsevier Science, 2021-12-02) Karacan, Yasemin; Yıldız, Hicran; Demircioğlu, Burçin; Ali, Rıdvan; Karacan, Yasemin; YILDIZ, HİCRAN; Demircioğlu, Burçin; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Fakültesi/Hemşirelik Bölümü.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; 0000-0001-8616-4935; 0000-0003-4241-5231; AAI-7132-2021; AAK-5246-2021; GQR-0671-2022; ESW-7456-2022; GXD-8209-2022Objective: Physiological and/or psychological problems that affect the quality of life of the patients occur depending on the diagnosis and treatment of hematological malignancies. Cancer treatment causes sexual problems such as infertility, vaginal dryness, and erectile dysfunction in the patients. Erectile dysfunction and loss of sexual desire are the most common sexual problems of men, while dyspareunia and loss of sexual desire are the most common sexual problems of women. This descriptive study was carried out to evaluate sexual problems and affecting factors in the patients with hematological cancer. Methods: Between July 1, 2011, and July 31, 2011, 45 sexually active patients who volunteered to participate in the study and whose written consents were obtained were included in the study. The data of the study were collected using the descriptive characteristics form prepared by the researchers based on the relevant literature and the Arizona Sexual Experiences Scale (ASEX). The scale scores range from 5 to 30 and a score of >11 above indicates sexual dysfunction. Results: Sexual dysfunction was observed in 62.2% of the patients. About 80.0% of women and 57.1% of men had sexual dysfunction. Sexual dysfunction was observed to be highest between the ages of 52-71 (81.2%) years. The mean total ASEX score was 15.90 +/- 4.25 in women and 13.34 +/- 5.37 in men. The ability to reach orgasm subscale score was found to differ by gender in the ASEX scale (P < 0.05). Conclusions: The prevalence of sexual dysfunction is high in the patients with hematological malignancies. It is recommended to evaluate these patients in terms of the presence of sexual dysfunction, as in the patients with other chronic diseases.Publication Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study(Galenos Yayincilik, 2020-01-01) Büyükaşık, Yahya; Turgut, Mehmet; Saydam, Güray; Yavuz, Selim; Ünal, Ali; Ar, Muhlis Cem; Ayyıldız, Orhan; Altuntaş, Fevzi; Okay, Mufide; Çiftçiler, Rafiye; Meletli, Özgür; Soyer, Nur; Mastanzade, Metban; Güven, Zeynep; Soysal, Teoman; Karakuş, Abdullah; Yiğenoğlu, Tuğce Nur; Uçar, Barış; Gökçen, Ece; Tuğlular, Tülin; Ali, Rıdvan; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; GXD-8209-2022Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV).Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers.Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%.Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females.Publication Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma: Early safety report of Turkish pass study(Ferrata Storti Foundation, 2015-06-01) Tuğlular, A. T. Fıratlı; Pehlivan, M.; Sarı, H. I.; Ayyıldız, M. O.; Saydam, G.; Sönmez, M.; Besisik, S. Kalayoğlu; Özgür, G.; Gürkan, E.; Kaynar, L.; Özet, G.; Demirkan, F.; Öngören, S.; Özdoğu, H.; Gündüz, E.; Tiftik, E. N.; Salim, O.; Turgut, M.; Hacıhanefioğlu, A.; Üre, U. B.; Özdemir, E.; Altuntas, F.; Şimsek, D.; Ulu, N.; Beksaç M.; Ali, R.; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp FakültesiPublication Nilotinib results in improved rates of molecular response in Turkish newly diagnosed CML-CP patients: A 24-month update(Ferrata Storti Foundation, 2015-06-01) Saydam, G.; Haznedaroğlu, I. C.; Kaynar, L.; Yavuz, A. S.; Ali, Rıdvan; Güvenç, B.; Akay, O. M.; Başlar, Z.; Özbek, U.; Sönmez, M.; Aydın, D.; Pehlivan, M.; Undar, B.; Dağdaş, S.; Ayyıldız, O. M.; Uar, B.; Dağ, I. M.; İlhan, O.; ALİ, RIDVAN; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı; GXD-8209-2022Publication Systemic inflammatory indices for predicting prognosis of myelofibrosis(Nature Portfolio, 2023-08-02) Ersal, Tuba; Özkocaman, Vildan; Pınar, İbrahim Ethem; Yalçın, Cumali; Orhan, Bedrettin; Candar, Ömer; Çubukcu, Sinem; Koca, Tuba Güllü; Hunutlu, Fazıl Çağrı; Yavuz, Şeyma; Ali, Ridvan; Özkalemkaş, Fahir; ERSAL, TUBA; ÖZKOCAMAN, VİLDAN; PINAR, İBRAHİM ETHEM; YALÇIN, CUMALİ; ORHAN, BEDRETTİN; CANDAR, ÖMER; ÇUBUKÇU, SİNEM; GÜLLÜ KOCA, TÛBA; HUNUTLU, FAZIL ÇAĞRI; YAVUZ, ŞEYMA; ALİ, RIDVAN; ÖZKALEMKAŞ, FAHİR; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı.; 0000-0001-9907-1498; 0000-0003-4168-2821; 0000-0003-3970-2344; 0000-0002-4991-9830; AAJ-4354-2021; FQG-8981-2022; JGM-6601-2023; KIE-5102-2024; ACW-2157-2022; EOZ-1609-2022; JJB-0254-2023; GWQ-5007-2022; KCK-7512-2024; GXS-5860-2022; GXD-8209-2022; JIW-1248-2023The impact of inflammatory markers such as systemic immune-inflammation (SII) index and systemic inflammation response index (SIRI) on myelofibrosis (MF) prognosis was evaluated for the first time in this study. Data from 60 patients diagnosed with MF between March 2011 and September 2022 were retrospectively analyzed. In addition to disease-related markers, the impact of SII and SIRI on prognosis was evaluated. In our study, the overall median survival (OS) was 64 months. OS was significantly shorter in patients older than 65 years, with high ferritin and lymphocyte levels, transfusion dependence at diagnosis, platelet count below 100 x 10(9)/L, Hb level below 8 g/dl, and high risk according to the dynamic international prognostic scoring system (DIPSS)-Plus score. When these variables were included in the multivariate Cox regression model, it was found that being older than 65 years, having a high ferritin value, being at high risk according to the DIPSS-plus score and Hb values below 8 increased the risk of death. Platelet-to-lymphocyte ratio (PLR) and SII index were lower in patients with a fatal outcome. No statistically significant relationship was found between SIRI and mortality. The findings of this study showed that low PLR and high ferritin were associated with poor prognosis in MF. Elevated SII and SIRI, evaluated for the first time in patients with myelofibrosis, did not predict prognosis. Since non-inflammatory variables play a role in the pathogenesis of MF, bone marrow indicators and systemic inflammation indicators derived from hematologic parameters may not be accurate.
- «
- 1 (current)
- 2
- 3
- »